Key result
Diabetic cardiomyopathy is driven by complex signaling defects, including dysregulated lipid metabolism and insulin resistance, which are targets for available and emerging therapeutic modalities.
This review summarizes the signaling defects underlying diabetic cardiomyopathy and discusses available and emerging therapeutic modalities.
Answers are grounded in this paper and cite their sources.
Therapeutic targeting of these pathways remains investigational; leaves open the need for prospective trials before clinical adoption.
Diabetes mellitus is the world's fastest growing disease with high morbidity and mortality rates, predominantly as a result of heart failure. A significant number of diabetic patients exhibit diabetic cardiomyopathy; that is, left ventricular dysfunction independent of coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy is complex, and is characterized by dysregulated lipid metabolism, insulin resistance, mitochondrial dysfunction and disturbances in adipokine secretion and signaling. These abnormalities lead to impaired calcium homeostasis, ultimately resulting in lusitropic and inotropic defects. This article discusses the impact of these hallmark factors in diabetic cardiomyopathy, and concludes with a survey of available and emerging therapeutic modalities.
No takes yet. Share an insight, caveat, or question.
Dobrin et al. (2010) conducted a review in Diabetic cardiomyopathy. Diabetic cardiomyopathy is driven by complex signaling defects, including dysregulated lipid metabolism and insulin resistance, which are targets for available and emerging therapeutic modalities.
Synapse has enriched 10 related papers. Consider them for comparative context: